Possibility of a continuously functioning, wearable or implantable artificial kidney

Researchers have developed a human nephron filter (HNF) that would eventually make possible a continuously functioning, wearable or implantable artificial kidney.

This study is published in the latest issue of Hemodialysis International.

The HNF is the first application in developing a renal replacement therapy (RRT) to potentially eliminate the need for dialysis or kidney transplantation in end-stage renal disease patients. The HNF utilizes a unique membrane system created through applied nanotechnology. In the ideal RRT device, this technology would be used to mimic the function of natural kidneys, continuously operating, and based on individual patient needs.

No dialysis solution would be used in the device. Operating 12 hours a day, seven days a week, the filtration rate of the HNF is double that of conventional hemodialysis administered three times a week.

“The HNF system, by eliminating dialysate and utilizing a novel membrane system, represents a breakthrough in renal replacement therapy based on the functioning of native kidneys,” say researchers. “The enhanced solute removal and wearable design should substantially improve patient outcomes and quality of life.”

According to the study, nearly 900,000 patients worldwide suffer from end-stage renal disease and require treatment through dialysis or transplantation. Animal studies using this technology are scheduled to begin in the next 1-2 years with clinical trials to follow subsequently.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Clinical trial highlights efficacy of imlifidase for kidney transplant recipients